Abstract:Cancer is a devastating disease and a large socio-economic burden. Novel therapeutic solutions are on the rise, although a cure remains elusive. Application of microorganisms represents an ancient therapeutic strategy, lately revoked and refined via simultaneous attenuation and amelioration of pathogenic properties. Salmonella Typhimurium has prevailed in preclinical development. Yet, using virulent strains for systemic treatment might cause severe side effects. In the present study, we highlight a modified strain based on Salmonella Typhimurium UK-1 expressing hexa-acylated Lipid A. We corroborate improved anti-tumor properties of this strain and investigate to which extent an intra-tumoral (i.t.) route of infection could help improve safety and retain advantages of systemic intravenous (i.v.) application. Our results show that i.t. infection exhibits therapeutic efficacy against CT26 and F1.A11 tumors similar to a systemic route of inoculation. Moreover, i.t. application allows extensive dose titration without compromising tumor colonization. Adverse colonization of healthy organs was generally reduced via i.t. infection and accompanied by less body weight loss of the murine host. Despite local application, adjuvanticity remained, and a CT26-specific CD8+ T cell response was effectively stimulated. Most interestingly, also secondary tumors could be targeted with this strategy, thereby extending the unique tumor targeting ability of Salmonella. The i.t. route of inoculation may reap the benefits of systemic infection and aid in safety assurance while directing potency of an oncolytic vector to where it is most needed, namely the primary tumor.

Advances in Salmonella Typhimurium-based Drug Delivery System for Cancer Therapy.

Genetically Engineered Salmonella Typhimurium: Recent Advances in Cancer Therapy.

Salmonella-based therapeutic strategies: improving tumor microenvironment and bringing new hope for cancer immunotherapy

Targeted Cancer Therapy Using Engineered Salmonella typhimurium.

Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.

Advances in bacteria‐based drug delivery systems for anti‐tumor therapy

New technologies in developing recombinant-attenuated bacteria for cancer therapy

New Technologies in Developing Recombinant‐attenuated Bacteria for Cancer Therapy

[Advances in Tumor-Therapy Using Genetically Modified Salmonella].

Recent advances in bacterial therapeutics based on sense and response

Bacterial Drug Delivery Systems for Cancer Therapy: “why” and “How”

Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles

Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection

Nanomedicine Hitchhiking on Bacteria for Treating Tumors

Recent advances in bacteria-mediated cancer therapy

Genetically Engineered Oncolytic Bacteria As Drug Delivery Systems for Targeted Cancer Theranostics

Oral Delivery of Tumor‐targeting Salmonella for Cancer Therapy in Murine Tumor Models

Engineered Bacteria: Strategies and Applications in Cancer Immunotherapy

Bacteria-mediated Cancer Therapy: A Versatile Bio-Sapper with Translational Potential

Harnessing and Mimicking Bacterial Features to Combat Cancer: From Living Entities to Artificial Mimicking Systems

Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery